Cited by 516Alzheimer's disease research and treatmentsCholesterol and Lipid MetabolismLipoproteins and Cardiovascular Health

Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism

Open access
Mahley, Robert W.·2016·Arteriosclerosis, Thrombosis, and Vascular Biology

Abstract

ApoE on high-density lipoproteins is primarily responsible for lipid transport and cholesterol homeostasis in the central nervous system (CNS). Normally produced mostly by astrocytes, apoE is also produced under neuropathologic conditions by neurons. ApoE on high-density lipoproteins is critical in redistributing cholesterol and phospholipids for membrane repair and remodeling. The 3 main structural isoforms differ in their effectiveness. Unlike apoE2 and apoE3, apoE4 has markedly altered CNS metabolism, is associated with Alzheimer disease and other neurodegenerative disorders, and is expressed at lower levels in brain and cerebrospinal fluid. ApoE4-expressing cultured astrocytes and neurons have reduced cholesterol and phospholipid secretion, decreased lipid-binding capacity, and increased intracellular degradation. Two structural features are responsible for apoE4 dysfunction: domain interaction, in which arginine-61 interacts ionically with glutamic acid-255, and a less stable conformation than apoE3 and apoE2. Blocking domain interaction by gene targeting (replacing arginine-61 with threonine) or by small-molecule structure correctors increases CNS apoE4 levels and lipid-binding capacity and decreases intracellular degradation. Small molecules (drugs) that disrupt domain interaction, so-called structure correctors, could prevent the apoE4-associated neuropathology by blocking the formation of neurotoxic fragments. Understanding how to modulate CNS cholesterol transport and metabolism is providing important insights into CNS health and disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/atvbaha.116.307023

Cites

113 of 113 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ApoE directly binds Aβ and, together with LDLR and LRP1, plays a key role in astrocyte-mediated Aβ clearance.

    “Importantly, ApoE appeared to directly bind Aβ and, together with its receptors LDLR and LRP1, to play a key role in astrocyte-mediated Aβ clearance [27,28].”

    From The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment (2024) · cites this paper as [27]

    The section “Role of LDL Receptor Family Members in ApoE Delivery of Cholesterol to CNS Cells” identifies LDLR and LRP1 as receptors involved in apoE-mediated lipoprotein uptake by neurons and glia. “ApoE-Associated Neuropathology” discusses Aβ clearance only as a possible benefit of enhancing apoE4 lipidation and says it remains unproven. Neither passage establishes direct apoE–Aβ binding or a key role for these receptors in astrocyte-mediated Aβ clearance; page numbers are unavailable in our copy. (LLM, conf=0.83)

    Experimental — accuracy not yet measured
  • The presence of the blood-brain barrier requires cholesterol in the brain to be synthesized de novo, primarily by astrocytes.

    “However, the presence of the blood–brain barrier requires cholesterol in the brain to be synthesized de novo, primarily by astrocytes (Jeske and Dietschy, 1980; Mahley, 2016).”

    From Sterol dysregulation in Smith–Lemli–Opitz syndrome causes astrocyte immune reactivity through microglia crosstalk (2022) · cites this paper as Mahley, 2016

    The Abstract says the blood–brain barrier restricts cholesterol entry and identifies astrocytes among the cells that synthesize CNS cholesterol. The ‘Cholesterol Synthesis and Metabolism in the CNS’ section says brain cholesterol is synthesized in situ and that adult production comes from glial cells and, to a lesser extent, neurons. Neither passage establishes that astrocytes specifically are the primary producers. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • ApoE is a central apolipoprotein in cerebral cholesterol metabolism and is involved in brain amyloid metabolism, blood brain barrier integrity, and transport of various lipid species to neuronal cells.

    “apoE is a central apolipoprotein in cerebral cholesterol metabolism and is involved in brain amyloid metabolism, blood brain barrier integrity, and transport of various lipid species to neuronal cells [15][16][17][18][19].”

    From APOE and vascular disease: Sequencing and genotyping in general population cohorts (2023) · cites this paper as [15]

    The Abstract identifies apoE as critical to CNS cholesterol and lipid transport, and “ApoE4 Structure Targets It for Degradation and Decreased Lipid Transport” says it delivers cholesterol and phospholipid to neurons. “ApoE-Associated Neuropathology” links apoE4 to amyloid deposition, but describes a proposed role in Aβ clearance as unproven. The passages on the blood–brain barrier describe its restriction of lipid movement, not a role for apoE in maintaining barrier integrity. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • ApoE4 association with lower ApoE level is more likely due to misfolding and accumulation of ApoE protein in the endoplasmic reticulum from an ionic interaction between Arg-61 in the N-terminal domain and Glu-255 in the C-terminal domain in the E4 isoform; this domain interaction is not present in the other two ApoE isoforms.

    “ii) more likely, it is the result of misfolding and accumulation of ApoE protein in endoplasmic reticulum due to an ionic interaction between Arg-61 in the N-terminal domain and Glu-255 in the C-terminal domain in the E4 isoform; this domain interaction is not present in the other two ApoE isoforms [3, 4].”

    From Genome-wide analysis identifies novel loci influencing plasma apolipoprotein E concentration and Alzheimer’s disease risk (2023) · cites this paper as [3]

    Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • ApoE is the major cholesterol carrier in the central nervous system; in the brain, lipids are transported on HDL-like particles where apoE is the primary apolipoprotein, unlike in the circulation where apoA1 is primary and apoE is present at lower levels.

    “ApoE is the major cholesterol carrier in the central nervous system: in the brain, lipids are transported on lipoproteins that resemble HDL particles, but while apolipoprotein A1 (apoA1) is the primary apolipoprotein and apoE is present in lower levels in HDL in the circulation, in contrast apoE is the primary apolipoprotein on these HDL-like particles found in the brain [67,73,75].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [38]Utermann G Genetic polymorphism of apolipoprotein E – impact on plasma lipoprotein metabolism Crepaldi G Tiengo A Baggio G Diabetes, Obesity and Hyperlipidemias – III Amsterdam Elsevier Science Publishers 1985 1 28

Cited by

Sorted by citations

Authors
Mahley, R. W.
Affiliations
University of California, San Francisco (US)
Corresponding author
Mahley, Robert W.
Venue
Arteriosclerosis, Thrombosis, and Vascular Biology
Published
2016-07
Volume
36
Issue
7
Pages
1305-1315
ISSN
  • 1079-5642 (ISSN-L)
  • 1524-4636
OpenAlex
W2560393860
Cited by
516
References
113
Citations by year
2026: 55 · 2025: 78 · 2024: 51 · 2023: 66 · 2022: 72 · 2021: 64 · 2020: 48 · 2019: 31 · 2018: 22 · 2017: 25 · 2016: 4
FWCI
21.98
Type
journal article
Language
en
Open access
Locations
  • Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Wellcome Trust (101786)
  • National Institute on Aging (R01AG028793)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
Keywords
apolipoprotein E, APOE ε4, APOE isoforms, high-density lipoprotein, cholesterol homeostasis, astrocytes, neurons, membrane lipid remodeling, Alzheimer's disease, domain interactions, neurodegenerative diseases, cerebrospinal fluid
MeSH terms
Alzheimer Disease, Animals, Apolipoproteins E, Astrocytes, Biological Transport, Central Nervous System, Cholesterol, Humans, Nerve Degeneration, Neurons, Protein Binding, Neurodegenerative Diseases, Models, Animal, Protein Interaction Domains and Motifs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review